This novel mechanism of action provides a valuable therapeutic alternative for patients with moderately to severely active IBD, particularly those who have had an inadequate response, lost response, or cannot tolerate conventional therapies or anti-TNF agents [9, 10]. This evidence concerns the gene TNF and inflammatory bowel disease.